LIMES Schlosskliniken AG (LIK.DE) • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold LIK.DE in your mock portfolio yet.
With an EPS of €19.09 and a PE ratio of 27.24, LIMES Schlosskliniken AG appears to be priced at a growth-oriented multiple, implying the market expects continued earnings strength. However, without detailed revenue, margin, and cash flow history, it is difficult to confirm whether current profitability is structurally strong or more cyclical. Valuation looks full rather than clearly cheap, suggesting expectations are already embedded in the price.
The stock trades at €520.00, about 26% above its 200‑day moving average of €412.50, signaling a strong medium‑term uptrend. A 5.3% gain over the last month confirms positive momentum, with no immediate sign in the data provided of trend exhaustion. From a purely technical standpoint, the setup appears constructive, though the elevated price versus long-term average can also mean higher downside risk if sentiment reverses.
Website traffic of roughly 20,553 visitors per month indicates a modest but tangible digital footprint, without evidence of rapid growth or contraction. Hiring appears stable with 28 job openings and no month‑over‑month change, suggesting neither aggressive expansion nor visible retrenchment. Social media presence is small and mixed—slight growth on Instagram, flat to slightly negative on YouTube, and a low LinkedIn follower base—pointing to limited but stable brand engagement rather than a strong growth signal.
Overall, LIMES Schlosskliniken AG presents a technically strong stock with a premium valuation and only modest support from alternative data signals. The uptrend and positive earnings justify some optimism, but the elevated PE and lack of strong growth cues from web traffic, hiring, or social media temper the outlook. On balance, the setup appears more neutral than clearly opportunistic, with performance likely sensitive to future earnings delivery.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started